Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952198 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
A Phase 1 study of Type 2 Diabetes, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 2
- Study locations
NCT00952198: Completed Phase 1 study of Type 2 Diabetes, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
NCT00952198 is a Phase 1 study of Type 2 Diabetes that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 128 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00952198, a Phase 1 study of Type 2 Diabetes, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.
Conditions Studied
Interventions
- DRUG Placebo; oral
- DRUG ARRY-403, glucokinase activator; oral
Study Locations (2)
California
- Profil Institute for Clinical Research - Chula Vista
Texas
- Cetero - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
What the finished NCT00952198 record still lists
NCT00952198 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo; oral is the first listed.
NCT00952198 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT00952198 about?
NCT00952198 is a clinical study titled "A Safety Study of ARRY-403 in Patients With Type 2 Diabetes". This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.
What is the current status of trial NCT00952198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2009-08. Estimated completion is 2010-08.
What conditions does trial NCT00952198 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00952198?
The interventions under investigation include: Placebo; oral (DRUG), ARRY-403, glucokinase activator; oral (DRUG).
Who is sponsoring clinical trial NCT00952198?
This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00952198 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00952198's enrollment target sits among peer trials
128 128th of 327 higher than 200 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia